We therefore investigated the clinicopathological, molecular, and prognostic characteristics of tumors harboring KRAS codon 61 and 146 mutations, utilizing a molecular pathological epidemiology[30,31] database of 1267 colorectal cancers from two U.S. nationwide prospective cohort studies. Here, KRAS is linked to colorectal cancer.